Navigating the delicate equilibrium of efficacy and quality of life in mHSPC treatment

Share :
Published: 6 Apr 2024
Views: 2610
Rating:
Save
Dr Antoni Vilaseca, Prof Gaëlle Fiard, Dr Miguel Ramírez-Backhaus and Prof Dr Christian Schwentner

Enjoy this interactive seminar from EAU 2024 in Paris, including case discussions.

Chair: Dr. Antoni Vilaseca and Prof. Gaëlle Fiard

Welcome & introduction:
Dr. Antoni Vilaseca and Prof. Gaëlle Fiard

The balancing act in mHSPC treatment – efficacy versus quality of life?:
Dr. Antoni Vilaseca, Prof. Gaëlle Fiard, Dr. Miguel Ramírez-Backhaus and Prof. Dr. Christian Schwentner

Clinical dilemmas in mHSPC – your challenging cases for the faculty:
Dr. Antoni Vilaseca, Prof. Gaëlle Fiard, Dr. Miguel Ramírez-Backhaus and Prof. Dr. Christian Schwentner

Summary and close:
Dr. Antoni Vilaseca and Prof Gaëlle Fiard

The session is part of a series of 3: http://ecancer.org/EAULive

 

This industry seminar is funded and organised by Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA and is intended for healthcare professionals only. Document for non-French physicians. Janssen-Cilag International NV.